Unima
Winter 2016InactiveFast and low-cost diagnostics for real time disease surveillance
Pressure-test this opportunity
Turn this teardown into a decision-ready prompt for ChatGPT, Claude, or your agent.
Fast and low-cost diagnostics for real time disease surveillance
Turn this teardown into a decision-ready prompt for ChatGPT, Claude, or your agent.
If you only have a few minutes to spare, here’s what investors, operators, and founders should know about Unima (W16).
Unima pursued a hard diagnostic brief: a low-cost paper test that could be read by a smartphone in about 15 minutes, without laboratory equipment, and feed results into disease-surveillance systems. The Mexican company grew from an animal-health biotechnology business into human tests for tuberculosis, HIV, and later COVID-19.
YC now labels Unima inactive and Dealroom labels it closed. The product lineage appears to continue at SolutionDx, whose site markets the same Find, Xplora, and Dxter names and says regulatory resubmission was needed after a change of ownership. No announcement identifies the transaction parties, effective date, price, or terms.
The company's history has two starting points. A family biotechnology venture began in 2006 and sold animal-health products from 2007. The human-diagnostics company is generally dated to 2015 and entered YC's Winter 2016 batch.
The founding family included Jose Luis Nuno Ayala, his brothers Alejandro and Rodrigo, and Laura Mendoza. Work with Mexican research center CICESE on pathogen detection moved from bovine tuberculosis and avian influenza toward human infectious disease testing.
Unima's system paired a disposable paper test with smartphone image analysis and a cloud reporting layer. A user placed a blood sample on the card, waited for a reaction pattern, and photographed it. The software interpreted the pattern and could send a geolocated result into a surveillance dashboard.
The product family targeted tuberculosis, HIV, and other infectious diseases. During COVID-19, Unima also worked on antibody and viral-detection approaches. The promise was not only a cheaper test; it was a connected test that could operate away from a laboratory.
SolutionDx now describes Find test cards, the Xplora smartphone reader, and the Dxter analytics layer. Its performance and approval statements are company claims unless supported by the cited regulator in a buying or clinical decision.
Unima targeted health ministries, public-health programs, nongovernmental organizations, clinics, and field workers in places where conventional labs were distant or expensive. The platform needed to work with limited infrastructure and inconsistent connectivity.
The burden of tuberculosis, HIV, and other infectious diseases is large, but the commercial market for one test depends on regulatory approval, procurement budgets, target-product profiles, confirmatory pathways, and country-specific programs. The reviewed sources do not support one reliable serviceable-market figure.
Unima competed with laboratory PCR and culture, microscopy, lateral-flow tests, cartridge systems such as GeneXpert, and public-health workflows already tied to national reporting. Its proposed edge was portability, price, and connected image reading. Its burden was clinical evidence, manufacturing quality, regulatory transfer, procurement, training, and confirmatory care.
The intended model combined test-card sales with smartphone analysis and surveillance software. Early profiles cited a $1 target per test, though no public source establishes achieved pricing, gross margin, or procurement volume.
Dealroom reports $850,000 raised in 2016 and $1.9 million in 2019. The company also used grants, accelerators, research partnerships, and technology licensing. No current revenue or commercial-volume evidence was found.
Read the complete post-mortem, the rebuild playbook, and the exact reasons Unima is still worth studying now.